Mamoei Sepehr, Jensen Henrik Boye, Pedersen Andreas Kristian, Nygaard Mikkel Karl Emil, Eskildsen Simon Fristed, Dalgas Ulrik, Stenager Egon
Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Department of Neurology, University Hospital of Southern Jutland, Sønderborg, Denmark.
Front Neurol. 2021 Oct 26;12:758710. doi: 10.3389/fneur.2021.758710. eCollection 2021.
Persons with multiple sclerosis (PwMS), already established as responders or non-responders to Fampridine treatment, were compared in terms of disability measures, physical and cognitive performance tests, neurophysiology, and magnetic resonance imaging (MRI) outcomes in a 1-year explorative longitudinal study. Data from a 1-year longitudinal study were analyzed. Examinations consisted of the timed 25-foot walk test (T25FW), six spot step test (SSST), nine-hole peg test (9-HPT), five times sit-to-stand test (5-STS), symbol digit modalities test (SDMT), transcranial magnetic stimulation (TMS) elicited motor evoked potentials (MEP) examining central motor conduction times (CMCT), peripheral motor conduction times (PMCT) and their amplitudes, electroneuronography (ENG) of the lower extremities, and brain structural MRI measures. Forty-one responders and eight non-responders to Fampridine treatment were examined. There were no intergroup differences except for the PMCT, where non-responders had prolonged conduction times compared to responders to Fampridine. Six spot step test was associated with CMCT throughout the study. After 1 year, CMCT was further prolonged and cortical MEP amplitudes decreased in both groups, while PMCT and ENG did not change. Throughout the study, CMCT was associated with the expanded disability status scale (EDSS) and 12-item multiple sclerosis walking scale (MSWS-12), while SDMT was associated with number of T2-weighted lesions, lesion load, and lesion load normalized to brain volume. Peripheral motor conduction time is prolonged in non-responders to Fampridine when compared to responders. Transcranial magnetic stimulation-elicited MEPs and SDMT can be used as markers of disability progression and lesion activity visualized by MRI, respectively. www.ClinicalTrials.gov, identifier: NCT03401307.
在一项为期1年的探索性纵向研究中，对已确定为对氨吡啶治疗有反应者或无反应者的多发性硬化症患者（PwMS），就残疾测量、身体和认知性能测试、神经生理学以及磁共振成像（MRI）结果进行了比较。分析了一项为期1年的纵向研究的数据。检查包括定时25英尺步行测试（T25FW）、六点步测试（SSST）、九孔插板测试（9-HPT）、五次坐立测试（5-STS）、符号数字模式测试（SDMT）、经颅磁刺激（TMS）诱发的运动诱发电位（MEP），用于检查中枢运动传导时间（CMCT）、外周运动传导时间（PMCT）及其振幅、下肢神经电图（ENG）以及脑结构MRI测量。对41名氨吡啶治疗反应者和8名无反应者进行了检查。除了PMCT外，两组之间没有差异，与氨吡啶反应者相比，无反应者的传导时间延长。在整个研究过程中，六点步测试与CMCT相关。1年后，两组的CMCT进一步延长，皮质MEP振幅降低，而PMCT和ENG没有变化。在整个研究过程中，CMCT与扩展残疾状态量表（EDSS）和12项多发性硬化症步行量表（MSWS-12）相关，而SDMT与T2加权病变数量、病变负荷以及按脑体积归一化的病变负荷相关。与反应者相比，氨吡啶无反应者的外周运动传导时间延长。经颅磁刺激诱发的MEP和SDMT可分别用作残疾进展和MRI显示的病变活动的标志物。www.ClinicalTrials.gov，标识符：NCT03401307。
